Pushing the Boundaries of Stem Cells
New Technique Expands Number of Functional Cord Blood Stem Cells for Transplantation
Source Newsroom: Mount Sinai Medical Center
Newswise — (NEW YORK – May 7) Adults suffering from diseases such as leukemia, lymphoma, and other blood-related disorders may benefit from life-saving treatment commonly used in pediatric patients. Researchers at the Icahn School of Medicine at Mount Sinai have identified a new technique that causes cord blood (CB) stems cells to generate in greater numbers making them more useful in adult transplantation.
The study, published in the May issue of The Journal of Clinical Investigation, looked at ways to expand the number of hematopoietic stem cells (HSC) in the laboratory required to replenish and renew blood cells. Cord blood stem cells have the ability to rapidly divide in the presence of combinations of growth factors but they often lose their marrow-repopulating potential following cell division. Researchers looked at ways to overcome this limitation by inducing a genetic program by which a stem cell retains its full functional properties after dividing in the laboratory.
“Cord blood stem cells have always posed limitations for adult patients because of the small number of stem cells present in a single collection,” said Pratima Chaurasia, PhD, Assistant Professor of Medicine at the Tisch Cancer Institute at Mount Sinai. “These limitations have resulted in a high rate of graft failure and delayed engraftment in adult patients.”
Researchers used a technique called epigenetic reprogramming which reshaped cell DNA by treating cells with a combination of histone deacetylase inhibitors (HDACI) and valproic acid. The VPA-treated cells produced a greater number of repopulating cells, and established multilineage hematopoiesis in primary, secondary and tertiary immune-deficient mice.
“We’re excited by these results. The findings have important implications for patients battling blood cancers and the difference between success and failure of life saving stem cell transplants.” added Ronald Hoffman, MD, Albert A. and Vera G. List Professor of Medicine, Director of Myeloproliferative Disorders Research Program at the Tisch Cancer Institute at Mount Sinai.
This study was supported by a New York Stem Cell Science grant from the Empire State Stem Cell Board, whose mission is to foster a strong stem cell research community in New York State and to accelerate the growth of scientific knowledge about stem cell biology and the development of therapies and diagnostic methods under the highest ethical, scientific, and medical standards for the purpose of alleviating disease and improving human health.
About the Mount Sinai Health System
The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven member hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care.
The System includes approximately 6,600 primary and specialty care physicians, 12-minority-owned free-standing ambulatory surgery centers, over 45 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island, as well as 31 affiliated community health centers. Physicians are affiliated with the Icahn School of Medicine at Mount Sinai, which is ranked among the top 20 medical schools both in National Institutes of Health funding and by U.S. News & World Report.
For more information, visit http://www.mountsinai.org, or find Mount Sinai on Facebook, Twitter and YouTube.
# # #